Cagrilintide Peptide: Benefits, Dosage, Side Effects & What the Research Says

Most people hear “weight loss peptide” and immediately think semaglutide. Maybe tirzepatide if they’ve been paying attention. But there’s a compound moving through Novo Nordisk’s pipeline right now that works through a completely different appetite system in your brain, and the results coming out of clinical trials are hard to ignore.

Cagrilintide. It’s an amylin analog. Not a GLP-1. Not a tweak on Ozempic. It targets a separate set of brain signals that GLP-1 drugs don’t even activate. The ones that tell you mid-meal “you’re full, put the fork down.”

When researchers combined cagrilintide with semaglutide and tested it on over 3,400 people, average weight loss hit 22.7%. Nearly a quarter of participants dropped 30% or more of their total body weight. On its own, cagrilintide produced 11.8% weight loss with fewer stomach issues than any GLP-1 drug currently available.

This guide covers what cagrilintide is, how it actually works, what every major clinical trial showed, dosing protocols, side effects from thousands of real participants, and where things stand heading into the FDA decision expected late 2026.

Quick Answer: What Is Cagrilintide?

What Is Cagrilintide and How Does It Work?

Your pancreas makes a hormone called amylin. Every time you eat, it gets released alongside insulin at roughly a 100:1 ratio. Its whole job is telling your brain “you’ve eaten enough.” Simple concept, but the drug industry has largely ignored amylin because the natural version is a nightmare to work with. It breaks down in about 15 minutes, clumps into toxic clusters, and doesn’t dissolve properly in your body.

There was one previous attempt to turn amylin into a drug. Pramlintide (brand name Symlin), approved back in 2005. It fixed the clumping problem but still needed 2 to 3 shots per day and only produced about 2 to 3% weight loss. Nobody was lining up for that.

Cagrilintide is what happens when a billion-dollar pharma company actually commits to solving those problems. Novo Nordisk’s chemistry team (published in the Journal of Medicinal Chemistry, 2021) made six targeted modifications to the amylin molecule. The most important: they attached a fatty acid chain that lets the peptide hitch a ride on albumin proteins in your blood, dragging the half-life from 15 minutes out to about 7 to 8 days. One shot per week instead of multiple daily injections. Same trick Novo used on semaglutide.

The other modifications fixed stability, solubility, and receptor potency. End result is a peptide (CAS 1415456-99-3, molecular weight ~4,409 Da) that’s stable, doesn’t clump, and activates all the relevant receptors. Structural imaging published in Nature Communications (2025) confirmed it binds all four amylin receptor subtypes plus the calcitonin receptor. Technically classified as a DACRA (dual amylin and calcitonin receptor agonist).

If you’re looking for research-grade cagrilintide, Amino Club is who I trust and recommend to BrainFlow readers. Third-party tested at 99%+ purity, great customer service, and the pricing is honestly hard to beat. You can grab 10mg of cagrilintide for under $50. Code BRAINFLOW saves 20% at checkout.

Why Amylin Is a Big Deal for Weight Loss

This is where cagrilintide separates itself from everything else, and it’s the part most people haven’t caught onto yet.

GLP-1 drugs like semaglutide reduce your overall sense of hunger. They work through appetite centers in a part of the brain called the hypothalamus. That’s one system. Amylin works through a completely different region called the area postrema, which sits in the hindbrain. It fires mid-meal to tell you “that’s enough food.”

Think of it this way. Semaglutide is the voice saying “you’re not really hungry today.” Cagrilintide is the signal saying “stop eating, this meal is done.” Two different messages, two different brain regions, two different sets of neurons. Researchers have confirmed these pathways don’t overlap.

But there’s more going on than just appetite. Amylin also changes how your brain processes food cravings at the dopamine level. Research shows it:

• Reduces the reward response to high-fat foods (the dopamine hit from junk food gets dialed down)
• Dampens compulsive eating patterns driven by opioid-like reward signals
• Reduces motivated food-seeking behavior in the central amygdala (with stronger effects seen in females)
• Slows gastric emptying through different vagal circuits than GLP-1

That late-night pizza impulse, the stress snacking, the “I’m not hungry but I want something.” Amylin touches those circuits in ways GLP-1 drugs don’t.

This is exactly why Novo Nordisk combined them into CagriSema. Amylin reducing meal size and cutting cravings through the hindbrain. GLP-1 suppressing baseline hunger through the hypothalamus. The REDEFINE 1 trial confirmed the payoff: 22.7% weight loss with the combo versus 16.1% with semaglutide alone versus 11.8% with cagrilintide alone.

Related: Best Peptides for Weight Loss: What the Research Shows

Clinical Trial Results (Every Major Study)

The clinical program behind cagrilintide involves over 4,600 participants across multiple trials, with results published in the New England Journal of Medicine and the Lancet. Not press releases. Peer-reviewed data in the top medical journals on earth.

Phase 1b: First Time Combining the Two

Published in the Lancet (Enebo et al., 2021). 96 participants, BMI 27-40, no diabetes, 20 weeks. The cagrilintide + semaglutide combination at 2.4 mg each produced 17.1% weight loss versus 9.8% with semaglutide alone. Adding amylin to the GLP-1 drug nearly doubled the result. No interaction between the two drugs was detected.

Phase 2: Cagrilintide Alone Beat Liraglutide

Lau et al., Lancet 2021. 706 people across 57 sites in 10 countries. Tested five doses of cagrilintide (0.3 to 4.5 mg weekly) against liraglutide (the daily GLP-1 injection behind Saxenda) and placebo over 26 weeks.

Weight loss ranged from 6.0% at the lowest dose to 10.8% at the highest, versus 3.0% on placebo. The standout: the top cagrilintide dose beat liraglutide 3.0 mg daily (10.8% vs 9.0%, P=0.03). A once-weekly amylin shot outperforming a daily GLP-1 injection. That turned heads.

REDEFINE 1: The Pivotal Trial

Garvey et al., New England Journal of Medicine 2025. This was the big one. 3,417 adults without type 2 diabetes. Four groups: CagriSema, semaglutide alone, cagrilintide alone, and placebo. 68 weeks.

Read those numbers again. 97.6% of people on CagriSema lost at least 5%. 6 out of 10 lost 20% or more. Nearly 1 in 4 lost 30%+. Blood pressure dropped ~10 mmHg (equivalent to adding a BP medication). 88% of people who entered the trial with prediabetes went back to normal blood sugar. Half of everyone on CagriSema went from obese to a BMI under 30.

One caveat: only about 57% of participants made it to the full dose because the trial allowed dose holds and reductions. The actual weight loss ceiling with optimized dosing could be higher, which is what the REDEFINE 11 trial is designed to figure out.

REDEFINE 2: Type 2 Diabetes

Davies et al., NEJM 2025. 1,206 T2D patients, 68 weeks. CagriSema produced 15.7% weight loss versus 3.1% on placebo. Blood sugar control was even more impressive: 73.5% of CagriSema patients hit HbA1c ≤6.5%, and CGM time-in-range reached 86.8%. That’s the kind of number that makes endocrinologists genuinely excited.

REDEFINE 4: Head-to-Head vs. Tirzepatide

This one made news for the wrong reasons. Announced February 23, 2026. Open-label trial, 84 weeks, 809 adults with obesity. CagriSema hit 23.0%. Tirzepatide (Zepbound) hit 25.5%. CagriSema didn’t meet non-inferiority. Novo Nordisk’s stock cratered about 15% overnight.

Some context though. The trial was open-label (everyone knew which drug they were on, which can skew results). Novo says the dose ramp wasn’t optimized for CagriSema. And 23% weight loss is still a massive result by any standard. Their response: a high-dose CagriSema trial (tripling semaglutide to 7.2 mg) starting later in 2026.

REIMAGINE 2: Superior to Semaglutide in Diabetes

Announced February 2, 2026. 2,728 T2D patients, 68 weeks. CagriSema was officially superior to semaglutide for both weight (14.2% vs 10.2%) and blood sugar (HbA1c dropped 1.91% vs 1.76%). The weight loss curve was still going down at 68 weeks. No plateau in sight.

For researchers following the amylin space, Amino Club carries cagrilintide at 99%+ purity for under $50 per 10mg vial. That’s significantly cheaper than most vendors charging $150-$250 for the same compound. Code BRAINFLOW takes another 20% off.

Why People Are Interested in Cagrilintide

Interest in cagrilintide research has exploded over the past year, and it’s coming from a few distinct directions.

Semaglutide plateau crowd. Millions of people on Wegovy or Ozempic right now have hit a wall. They lost 12%, maybe 15%, and then stalled. Adding amylin gives the body a completely different appetite signal. In REDEFINE 1, CagriSema produced about 6.6 percentage points more weight loss than semaglutide alone. For someone stuck at 180, that’s the difference between plateauing and actually reaching their goal weight.

People who can’t tolerate GLP-1 side effects. Semaglutide makes a lot of people miserable. The nausea, the vomiting, the constant GI distress. Data from multiple studies shows cagrilintide on its own has lower rates of nausea and vomiting than semaglutide or liraglutide. At 11.8% weight loss with a gentler side effect profile, standalone cagrilintide is a real alternative for people who tried GLP-1 drugs and couldn’t hack it.

Type 2 diabetes patients. About 90% of American adults with diabetes also carry excess weight. CagriSema tackles both at once: 15.7% weight loss plus 73.5% of patients hitting healthy blood sugar levels from a single weekly injection.

Peptide research community. People who track clinical trials and investigate novel mechanisms. The amylin pathway is genuinely new ground. The dopamine-modulating, reward-pathway effects make it especially interesting for anyone researching compulsive eating or food addiction models.

Related: GLP-1 Plateau? Reasons Your Weight Loss Stalled and How to Fix It

Cagrilintide Dosage: What the Trials Used

Every dosing protocol in the cagrilintide clinical program follows the same idea: start low and work your way up over about 4 months. Jump straight to the full dose and the nausea will be brutal. The slow ramp gives your body time to adjust.

Standalone cagrilintide was tested at 0.3 to 4.5 mg per week in Phase 2. The 2.4 mg dose became the standard going forward.

Both drugs go up together, increasing every 4 weeks until you hit full maintenance at week 17. Subcutaneous injection, once a week, in the abdomen, thigh, or upper arm with site rotation. Same day every week, any time of day, food doesn’t matter.

Weeks 9 through 16 tend to be the roughest for stomach issues because doses are climbing fastest. Most people who pushed through that window saw things settle down at maintenance. Novo is also testing lower-dose combinations (1.0/1.0 mg and 1.7/1.7 mg) in the REDEFINE 9 trial for people who want solid results with potentially fewer side effects.

Side Effects and Safety

Stomach stuff is the main issue. When you’re activating two separate appetite systems that both affect digestion, your gut is going to push back, especially while doses are ramping up.

From REDEFINE 1 (3,417 participants, 68 weeks):

55% nausea looks scary on paper. But 99.5% of all stomach events were non-serious, and 98.1% were mild or moderate. They cluster during dose escalation (weeks 9-16) and fade at maintenance. Only 6% quit because of side effects, which is lower than retatrutide’s 12-18% dropout rate.

Something that gets overlooked: cagrilintide by itself is actually gentler on the stomach than GLP-1 drugs. Studies showed lower nausea and vomiting rates with cagrilintide monotherapy versus semaglutide or liraglutide. The higher CagriSema numbers come from stacking both pathways.

Fat Loss vs. Muscle Loss: Body Composition Data

When you lose over 20% of your body weight, how much of that is muscle? This is the question everyone asks.

DXA body scan data from 252 REDEFINE 1 participants (presented at ObesityWeek 2025) showed CagriSema’s weight loss broke down to roughly 67% fat and 33% lean tissue. Semaglutide alone was about 70/30. Tirzepatide came in slightly better at roughly 75/25 based on SURMOUNT-1 data.

Tirzepatide looks a bit better at preserving muscle. But there’s a detail most coverage misses: among CagriSema participants who lost 30%+ of their body weight, the proportion of lean mass relative to total body weight actually went up. From 51.3% lean at baseline to 63.2% at 68 weeks. You’re shedding fat so much faster than muscle that your body composition ratio improves even though absolute lean mass decreases.

Early lab research suggests amylin may preferentially target fat tissue, though that needs more data. REDEFINE 8 (104 weeks with DXA, ~400 participants) will give a clearer answer.

No matter what compound you’re researching, resistance training and adequate protein aren’t optional with significant weight loss. Peptides drive the fat off. They don’t build muscle back. That’s on you and the barbell.

Related: BPC-157 Complete Guide: Benefits, Dosage & What to Know

Cagrilintide vs. Tirzepatide vs. Retatrutide vs. Semaglutide

Tirzepatide is the current king. 25.5% in the direct matchup. Retatrutide is the next wave at 28.7%. CagriSema’s advantage is that it’s the furthest along of any next-gen combination, has the lowest dropout rate at 6%, and targets a pathway no approved drug covers.

Amycretin (zenagamtide) is the wildcard, and it’s actually Novo Nordisk’s own compound. Single molecule that does what CagriSema does in one peptide instead of two. Early data showed 22-24.3% at just 36 weeks with the curve still trending down. There’s an oral version in development too. If amycretin delivers, it could make CagriSema look like a stepping stone.

If you’re researching amylin analogs or weight management peptides, Amino Club carries cagrilintide at 99%+ purity for under $50 per 10mg. That’s a fraction of what most vendors charge. Code BRAINFLOW saves 20%.

FDA Status and Legal Landscape (March 2026)

Cagrilintide is not approved by the FDA. Not standalone. Not in combination. Not anywhere.

CagriSema’s NDA was filed December 18, 2025. Since the FDA evaluates against placebo (not competitors), the REDEFINE 4 loss to tirzepatide doesn’t affect approval. Expect a decision around October-November 2026 if standard 10-month review applies.

Compounding is off the table. The FDA stated explicitly cagrilintide “cannot be used in compounding under federal law.” It was never approved, never on the shortage list, and never qualified for the compounding exemption that briefly covered semaglutide. In September 2025, the FDA sent over 40 warning letters to compounding pharmacies, specifically naming cagrilintide. The Alliance for Pharmacy Compounding told members not to touch it.

Research peptide vendors are the only current source. Cagrilintide is sold as lyophilized powder under the “research use only” framework. Quality and testing vary hugely between vendors.

What’s Coming Next in the Pipeline

Several major trials will answer the remaining questions over the next 1-3 years:

• REDEFINE 3 — Cardiovascular outcomes trial (~7,000 participants). Will CagriSema reduce heart attacks and strokes? Won’t read out for 3+ years, but a positive result would be massive for insurance coverage.
• REDEFINE 8 — Long-term body composition study (104 weeks with DXA, ~400 people). This will answer the lean mass question with real data.
• REDEFINE 11 — Extended duration with optimized dosing (80wk + 80wk extension, ~600 people). Should reveal the true weight loss ceiling. Data expected H1 2027.
• High-dose CagriSema (2.4 mg cagrilintide / 7.2 mg semaglutide) — Phase 3 starting H2 2026. This is Novo’s answer to the tirzepatide loss. If tripling semaglutide pushes past 25%, it changes everything.
• RENEW program — Standalone cagrilintide Phase 3. For people who can’t tolerate GLP-1 drugs at all, this could create an entirely new treatment category.

Patent protection for CagriSema runs through the late 2030s. Generic versions are very unlikely before 2038-2040.

Where to Get Research-Grade Cagrilintide

There are tons of vendors selling cagrilintide online right now. Most popped up in the last year chasing the weight loss peptide boom. Some are legit. Some are selling mystery powder with no testing behind it. When you’re dealing with a newer compound like this, you want a vendor with a real reputation.

Amino Club is the recommendation, same as it’s been for BrainFlow readers. Their reputation in the peptide community is solid. Every product is third-party tested at 99%+ purity. Customer service is responsive and actually helpful (rarer than it should be in this space). And the pricing is genuinely unbeatable: 10mg of research-grade cagrilintide for under $50. Most vendors charge three to five times that.

I’ve used them across multiple compounds and the quality has been consistent every time. That matters. You need to know what’s in the vial is what the label says, at the purity they claim.

Standard disclaimer: research peptides are sold under the “not for human consumption” framework. Unverified purity from bad vendors, contamination risk, no medical supervision. Know what you’re getting into.

Frequently Asked Questions

What is cagrilintide?

A long-acting synthetic analog of amylin, a hormone your pancreas releases alongside insulin to signal fullness. Cagrilintide activates amylin receptors in the hindbrain to reduce appetite, dampen food cravings, and slow gastric emptying through a pathway completely separate from GLP-1 drugs. It was developed by Novo Nordisk with a half-life of 7-8 days, allowing once-weekly injection.

What is CagriSema?

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg + semaglutide 2.4 mg delivered as a single once-weekly injection. The two peptides are kept in separate chambers of a dual-pen injector because they need different pH levels for stability. Novo Nordisk filed an NDA in December 2025, with an FDA decision expected late 2026.

How much weight can you lose with cagrilintide?

As a standalone compound, cagrilintide produced 11.8% weight loss over 68 weeks in the REDEFINE 1 trial. Combined with semaglutide (as CagriSema), it produced 22.7%. Nearly a quarter of CagriSema participants lost 30% or more of their body weight.

How does cagrilintide differ from semaglutide?

Semaglutide is a GLP-1 receptor agonist that suppresses appetite through hypothalamic brain centers. Cagrilintide is an amylin analog that signals satiety through the hindbrain (area postrema) and reduces dopamine-driven food cravings. They target different receptor systems on different neurons, which is why combining them produces more weight loss than either alone.

Is cagrilintide FDA approved?

No. As of March 2026, cagrilintide is not FDA-approved for any use, either standalone or in combination. CagriSema’s NDA was filed in December 2025, with a decision expected around October-November 2026. Cagrilintide cannot legally be compounded in the US.

What are the side effects of cagrilintide?

GI side effects dominate: nausea (55%), constipation (30.7%), and vomiting (26.1%) with CagriSema. Almost all were mild-to-moderate and resolved after dose escalation. Only 6% of participants discontinued. Cagrilintide alone has lower GI side effects than semaglutide or liraglutide.

Did CagriSema beat tirzepatide?

No. In the REDEFINE 4 head-to-head trial, CagriSema achieved 23.0% weight loss versus tirzepatide’s 25.5% at 84 weeks. Non-inferiority was not met. The trial was open-label, which may have introduced bias. Novo Nordisk is planning a high-dose CagriSema trial (2.4/7.2 mg) to try closing the gap.

Can you buy cagrilintide?

Cagrilintide is available as a research peptide from vendors like Amino Club, sold as lyophilized powder under the “research use only” framework. It cannot be legally compounded in the US. The FDA sent 40+ warning letters to compounding pharmacies in September 2025 specifically flagging cagrilintide.

What is amycretin/zenagamtide?

Amycretin (now called zenagamtide) is Novo Nordisk’s next-generation single molecule that activates both GLP-1 and amylin receptors. It does what CagriSema does in one peptide instead of two, with an oral formulation in development. Phase 1b/2a data showed 22-24.3% weight loss at just 36 weeks with the curve still going down. Phase 3 started in early 2026.

The Bottom Line

Cagrilintide is the most interesting compound in the obesity drug pipeline right now. Not because it posted the single biggest weight loss number (retatrutide has that at 28.7%). But because it cracks open an entirely new pathway that nothing else on the market touches.

Amylin reduces how much you eat at each meal. It dials down the dopamine-driven cravings. It quiets compulsive eating signals. And it does all of this through brain circuits that GLP-1 drugs can’t reach. When you combine that with semaglutide, you get 22.7% average weight loss. 88% prediabetes reversal. Blood pressure drops equivalent to adding a medication. Nearly 1 in 4 people losing 30%+ of their body weight.

Yeah, tirzepatide beat it head-to-head (25.5% vs 23%). But these drugs work through completely different mechanisms, and the amylin pathway brings something to the table that no GIP or GLP-1 agonist can replicate. A high-dose CagriSema trial starting later this year could close the gap.

Whether CagriSema becomes a long-term fixture or gets leapfrogged by amycretin (Novo’s own single-molecule version with an oral option in development) is an open question. Either way, the amylin pathway has been validated by some of the best clinical data in obesity research history. That science is here to stay.

For anyone researching cagrilintide, Amino Club is the source I trust and the one BrainFlow readers keep coming back to. 99%+ purity, third-party tested, under $50 for 10mg, and customer service that actually picks up. Code BRAINFLOW saves 20%.

References

1. Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-94. PMID: 34288673
2. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. Lancet. 2021;397:1736-48. PMID: 33894838
3. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet. 2021;398:2160-72. PMID: 34798060
4. Garvey WT, et al. CagriSema for weight management (REDEFINE 1). N Engl J Med. 2025;393:635-47. PMID: 40544433
5. Davies MJ, et al. CagriSema in type 2 diabetes (REDEFINE 2). N Engl J Med. 2025;393:648-59. PMID: 40544432
6. Cryo-EM structures of cagrilintide bound to amylin and calcitonin receptors. Nat Commun. 2025. PMID: 40204768
7. Dutta D, et al. Cagrilintide and CagriSema meta-analysis. Indian J Endocrinol Metab. 2024;28(5):436-44. PMID: 39676787
8. Frias JP, et al. CagriSema in type 2 diabetes (Phase 2). Lancet. 2023;402:720-30. PMID: 37364590